Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

24.05.22	Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study (PR Newswire)
23.05.22	Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA (PR Newswire)
20.05.22	Lilly : CHMP Issues Positive Opinion For Olumiant For Severe Alopecia Areata Treatment (RTTNews)
20.05.22	CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) (PR Newswire)
19.05.22	Statement of changes in beneficial ownership of securities (RSS)
18.05.22	Statement of changes in beneficial ownership of securities (RSS)
17.05.22	Statement of changes in beneficial ownership of securities (RSS)
16.05.22	Lilly to Participate in UBS Global Healthcare Conference 2022 (PR Newswire)
14.05.22	FDA Approves Lilly's Mounjaro Injection For Type 2 Diabetes Treatment (RTTNews)
13.05.22	FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes (PR Newswire)
11.05.22	Eli Lilly, Incyte Announce FDA Approval Of OLUMIANT For Hospitalized Patients With COVID-19 (RTTNews)
11.05.22	FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 (PR Newswire)
06.05.22	Mary Lynne Hedley Elected to Lilly Board of Directors (PR Newswire)
03.05.22	Lilly to Participate in Bank of America Securities 2022 Healthcare Conference (PR Newswire)
02.05.22	Lilly Declares Second-Quarter 2022 Dividend (PR Newswire)
28.04.22	Lilly: Tirzepatide In SURMOUNT-1 Trial Delivers Superior Weight Loss In Adults (RTTNews)
28.04.22	Eli Lilly Q1 Results Top Estimates; Boosts FY22 Revenue Outlook (RTTNews)
28.04.22	Eli Lilly And Co. Reveals Increase In Q1 Profit (RTTNews)
28.04.22	Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022 (PR Newswire)
28.04.22	Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1 (PR Newswire)
28.04.22	Ausblick: Eli Lilly and verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) Bei Eli Lilly and stehen Quartalszahlen ins Haus. Was Experten erwarten.» mehr
26.04.22	Bachem-Aktie springt hoch: Bachem kooperiert mit Eli Lilly (AWP) Das Biochemie-Unternehmen Bachem geht eine strategische Partnerschaft mit Eli Lilly and Company ein.» mehr
20.04.22	Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care (PR Newswire)
19.04.22	Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement (PR Newswire)
19.04.22	Form 4 59478 (RSS)
14.04.22	Pharmaindustrie: Angebot von Corona-Impfstoffen übersteigt Nachfrage (AWP)
13.04.22	Erste Schätzungen: Eli Lilly and verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)
11.04.22	Lilly's Lebrikizumab - Corticosteroids Show Improvements In Disease Severity For Atopic Dermatitis (RTTNews)
11.04.22	Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis (PR Newswire)
07.04.22	Form 4 59478 (RSS)
01.04.22	Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress (PR Newswire)
29.03.22	Form 4 59478 (RSS)
28.03.22	Innovent Biologics, Lilly Expand Partnership In Oncology (RTTNews)
28.03.22	Innovent and Lilly Expand Strategic Partnership in Oncology (PR Newswire)
26.03.22	Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies (PR Newswire)
26.03.22	Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies (PR Newswire)
24.03.22	Eli Lilly: FDA Issues CRL For BLA For Sintilimab; Unable To Approve Application In Its Current Form (RTTNews)
24.03.22	Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer (PR Newswire)
18.03.22	Statement of changes in beneficial ownership of securities (RSS)
17.03.22	Form 4 59478 (RSS)
16.03.22	Eli Lilly: EMPA-KIDNEY Trial Shows Efficacy For Jardiance At Early Stage; Trial To Stop (RTTNews)
16.03.22	Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease (PR Newswire)
14.03.22	Boeing : Arajet Orders 20 737 MAX Aircraft (RTTNews)
08.03.22	Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR) (PR Newswire)
07.03.22	Form 4 59478 (RSS)
03.03.22	Lilly to Participate in Barclays Global Healthcare Conference (PR Newswire)
01.03.22	Eli Lilly Says Jardiance Provides Significant Benefit In Adults Following Acute Heart Failure (RTTNews)
01.03.22	Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial (PR Newswire)
28.02.22	Lilly to Participate in Cowen Health Care Conference (PR Newswire)
28.02.22	Biotech Stocks Facing FDA Decision In March 2022 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus
20.12.24		Handel in Zürich: SMI verbucht Verluste
20.12.24		Börse Frankfurt: So steht der LUS-DAX am Nachmittag

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten

20.12.24

Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus